Market Place
Sourcing Support
COSCIENS Updates On Merger Integration And Development Plans
23 Sep 2024 //
GLOBENEWSWIRE
Aeterna Zentaris and Ceapro Complete Merger Transaction
03 Jun 2024 //
GLOBENEWSWIRE
Ceapro Q1 2024 Results And Business Update
29 May 2024 //
GLOBENEWSWIRE
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
29 Apr 2024 //
GLOBENEWSWIRE
Aeterna Zentaris & Ceapro Merger Approved by Securityholders at Special Meetings
12 Mar 2024 //
GLOBENEWSWIRE
Ceapro Provides Business Update on Progress of Ongoing Development Programs
23 Feb 2024 //
GLOBENEWSWIRE
Ceapro Inc. Announces the Mailing of Meeting Materials
15 Feb 2024 //
GLOBENEWSWIRE
Aeterna Zentaris and Ceapro Announce Merger of Equals
14 Dec 2023 //
GLOBENEWSWIRE
Ceapro Announces Dosing of First Patients in Ph 1-2a Assessing Avenanthramides
13 Dec 2023 //
GLOBENEWSWIRE
Ceapro Inc. Reports 2023 Third Quarter Financial Results
29 Nov 2023 //
GLOBENEWSWIRE
Ceapro Initiates Phase 1-2a Study Assessing Flagship Product Avenanthramides
27 Nov 2023 //
GLOBENEWSWIRE
Ceapro Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH
07 Nov 2023 //
GLOBENEWSWIRE
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results
29 Aug 2023 //
GLOBENEWSWIRE
Ceapro Extends International Supply and Distribution Agreement with Symrise
25 Aug 2023 //
GLOBENEWSWIRE
Ceapro Announces Next Phase of Collaboration with the Angiogenesis Foundation
18 Jul 2023 //
GLOBENEWSWIRE
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
05 Jul 2023 //
GLOBENEWSWIRE
Ceapro Announces Results of 2023 Shareholders Meeting
07 Jun 2023 //
GLOBENEWSWIRE
Ceapro Inc. Reports Financial Results for First Quarter 2023
25 May 2023 //
GLOBENEWSWIRE
Ceapro Inc. Presents Encouraging Results from Study with McMaster University
23 May 2023 //
GLOBENEWSWIRE
Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan
03 May 2023 //
GLOBENEWSWIRE
Ceapro Inc. Appoints Michel Regnier as SVP, Technical Operations
27 Apr 2023 //
GLOBENEWSWIRE
Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights
12 Apr 2023 //
GLOBENEWSWIRE
Ceapro Announces Data from Research Collaboration with McMaster University
23 Mar 2023 //
GLOBENEWSWIRE
Ceapro Announces Collaboration with the Angiogenesis Foundation
07 Mar 2023 //
GLOBENEWSWIRE
Ceapro Inc. Recognized as a Top 50 TSX Venture Exchange Company
21 Feb 2023 //
GLOBENEWSWIRE
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
10 Jan 2023 //
GLOBENEWSWIRE
Health Canada grants clearance for Ceapro’s anti-inflammatory therapy trial
23 Dec 2022 //
CLINICALTRIALSARENA
Ceapro Receives Approval from Health Canada to Commence Ph 1/2a Human Trial
22 Dec 2022 //
GLOBENEWSWIRE
Ceapro Inc. Launches Next Phase of Scale Up for its Disruptive PGX Technology
07 Nov 2022 //
GLOBENEWSWIRE
Ceapro Announces +ve Data from Bioavailability Studies Evaluating CoQ10
13 Oct 2022 //
GLOBENEWSWIRE
Ceapro Reports Record 2022 Q2 and Six-Month Financial Results
24 Aug 2022 //
GLOBENEWSWIRE
Ceapro and McMaster extend partnership to develop Covid-19 therapy
12 Aug 2022 //
PHARMACEUTICAL-TECHNOLOGY
Ceapro Inc. Expands Collaborative Research Program with McMaster University
11 Aug 2022 //
GLOBENEWSWIRE
Ceapro to publish +ve Results for PGX-Processed Alginates Impregnated with CoQ10
09 Aug 2022 //
GLOBENEWSWIRE
Ceapro Bolsters Executive Management Team; Appoints Sigrun Watson as CRO
12 Jul 2022 //
GLOBENEWSWIRE
Ceapro Announces Results of 2022 Shareholders Meeting
07 Jun 2022 //
GLOBENEWSWIRE
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
23 May 2022 //
GLOBENEWSWIRE
Ceapro Inc. Present PGX Enabling Technology Case Study
13 May 2022 //
GLOBENEWSWIRE
Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates
11 May 2022 //
GLOBENEWSWIRE
Ceapro Inc. Announces Appointment of Genevi Foster to Board of Directors
19 Apr 2022 //
GLOBENEWSWIRE
Ceapro Reports Q4 and Full Year 2021 Financial Results
13 Apr 2022 //
GLOBENEWSWIRE
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Symrise
10 Mar 2022 //
GLOBENEWSWIRE
Ceapro Bolsters Board of Directors; Appoints Top Executive
02 Mar 2022 //
GLOBENEWSWIRE
Ceapro Inc. Announces R&D Funding to Support PGX Technology Project
29 Nov 2021 //
GLOBENEWSWIRE
Ceapro Reports Preliminary Results from Clinical Trial Evaluating Oat Beta
17 Nov 2021 //
GLOBENEWSWIRE
Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results
17 Nov 2021 //
GLOBENEWSWIRE
Ceapro Develops Inhalable Therapeutic Using Yeast Beta Glucan & PGX-YBG
11 Nov 2021 //
GLOBENEWSWIRE
Ceapro Inc. Reports 2021 Second Quarter and Six-Month Financial Results
26 Aug 2021 //
GLOBENEWSWIRE
Ceapro Inc. Enters into Research Collaboration with the Angiogenesis Foundation
23 Aug 2021 //
GLOBENEWSWIRE
Ceapro Provides Update on Development of an Inhalable Therapeutic
18 Aug 2020 //
GLOBENEWSWIRE
